There is a serious worldwide shortage of recombinant factor VIII, a critical blood-clotting protein that hemophilic patients use to prevent and control their bleeds, according to the National ...

Factor VIII gene was introduced into hematopoietic stem cells in men with hemophilia. The annualized bleeding rate went from 10 to 0. No worrisome gene integrations were seen. The content of this ...

If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration.

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that ...

This therapy used their own blood stem cells, modified to carry a special gene that helps produce the clotting protein factor VIII, which people with haemophilia A lack. Unlike traditional ...

Antihemophilic Factor VIII (human) 250 IU, 500 IU, 1000 IU; per bottle; dried concentrate for IV infusion after reconstitution; contains albumin. Dosage Required (IU) = Body Weight (kg ...

"The patients were followed up for six months after undergoing the therapy. Median factor-VIII levels were assessed during the treatment and excellent outcomes were observed. The gene therapy with ...